Skip to content
2026 Tumor Board Tuesday Evaluation
Evaluation
In order to receive a CME certificate for your participation in this activity, please complete this survey in its entirety. Please allow 4 weeks for your certificate to be processed.
*
1.
What is your degree?
(Required.)
MD/DO
NP
PA
Pharmacist
Nurse
Other (please specify)
*
2.
What is your specialty?
(Required.)
Med/Surg/Rad/IR Onc
Other MD, APP, RN, PharmD
Patient/Patient Advocate
Fellow, Resident, Trainee
*
3.
How many years have you been in practice?
(Required.)
>21
11-20
1-10
<1
*
4.
How many patients with advanced or metastatic cancers do you treat each week?
(Required.)
1 to 10
11 to 25
26 to 50
I am not directly involved in patient care
*
5.
Please select the option that best describes your practice:
(Required.)
Academic Clinician
Community Clinician
Other (please specify)
*
6.
The content presented:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Enhanced my current knowledge base
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Addressed my most pressing questions
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Promoted improvements or quality in health care
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Was scientifically rigorous and evidence based
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
7.
These activities were free from commercial bias.
(Required.)
Yes
No (please explain)
*
8.
Which new strategies/skills/information will you apply to your area of practice? Select all that apply
(Required.)
Better understanding of molecular alterations in advanced or metastatic cancers and their impact on therapeutic decision making
Better able to utilize best practices when transitioning therapies
Elucidate the genomic, immunogenic, and proteomic aberrations that serve as molecular drivers for a wide variety of solid tumors
Mandate the necessity for a personalized approach to treatment when dealing with solid tumors
Select personalized treatments for patients with breast, gastrointestinal, genitourinary, and lung cancer based on the characteristics of each patient and the molecular profile of each tumor
Assess treatments currently in late-phase development that are being studied for their ability to address actionable molecular targets common to disease state subsets within breast, gastrointestinal, genitourinary, and lung cancers
Integrate strategies to monitor and proactively plan to mitigate treatment related side effects
*
9.
How committed are you to making changes in your practice based on your participation in these activities?
(Required.)
Very Committed
Committed
Neutral
Not committed
I do not plan to make changes
10.
As a result of your participation in these activities, what is the one change you are most likely to implement in your practice?
*
11.
What barriers do you see to making changes in your practice? Select all that apply.
(Required.)
Lack of knowledge regarding evidence-based strategies
Lack of convincing evidence to warrant change
Lack of time/resource to consider change
Insurance, reimbursement, or legal issues
Conflicting guidelines and/or evidence
Patient compliance and/or patient resource barriers
Other (please specify)
12.
Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities: